The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase 2 study of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy in patients with refractory metastatic pancreatic cancer (CHECKPAC).
 
Inna Markovna Chen
Consulting or Advisory Role - Amgen
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Genis (Inst); Roche Belgium (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Celgene; Roche
 
Julia S. Johansen
No Relationships to Disclose
 
Susann Theile
No Relationships to Disclose
 
Jessica X. Hjaltelin
No Relationships to Disclose
 
Sif I. Novitski
No Relationships to Disclose
 
Søren Brunak
Leadership - Intomics; ProScion A/S
Stock and Other Ownership Interests - Hoba Therapeutics; Intomics; Lundbeck; Novo Nordisk
 
Jane P. Hasselby
No Relationships to Disclose
 
Gro L. Willemoe
No Relationships to Disclose
 
Torben Lorentzen
No Relationships to Disclose
 
Kasper Madsen
No Relationships to Disclose
 
Benny V. Jensen
No Relationships to Disclose
 
Eva E. Wilken
No Relationships to Disclose
 
Poul F. Geertsen
Research Funding - Bristol Myers Squibb (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
 
Claus Behrens
No Relationships to Disclose
 
Christian Nolsoe
No Relationships to Disclose
 
Kirstine L. Hermann
No Relationships to Disclose
 
Inge Marie Svane
Leadership - IO Biotech
Stock and Other Ownership Interests - IO Biotech
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche
Research Funding - Adaptimmune (Inst); Enara Bio (Inst); Evaxion Biotech (Inst); Lytix Biopharma (Inst); TILT Biotherapeutics (Inst)
Other Relationship - Bristol-Myers Squibb; Lytix Biopharma; MSD; Novartis; Roche; TILT Biotherapeutics
 
Dorte Nielsen
Other Relationship - Boehringer Ingelheim; Genmab; Lilly; Merck; MSD